3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
7
Tumor-Agnostic
3
Gastrointestinal
3
Breast
3
Other solid neoplasm
2
Head & Neck
2
Gynecologic
2
Other hematologic neoplasm
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
pembrolizumab
26
Pemetrexed
26
Cisplatin
25
Nivolumab
22
Carboplatin
16
Paclitaxel
14
Gemcitabine
12
Ipilimumab
11
tislelizumab
8
durvalumab
8
Ramucirumab
8
Docetaxel
8
talazoparib
7
Fluorouracil
7
Radiotherapy
6
Capecitabine
6
tremelimumab
5
cobimetinib
5
atezolizumab
5
adavosertib
5
Radiosurgery
5
Cyclophosphamide
5
Bevacizumab
5
olaparib
4
avelumab
4
Temozolomide
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
bintrafusp alfa protein, human
×
Other solid neoplasm
×
Clear all
NCT04457778
2026-05-04
First in Human Study of M6223
EMD Serono
Phase 1
Completed
58 enrolled
38 charts
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts